Untargeted and Semi-Targeted Metabolomics Approach for Profiling Small Intestinal and Fecal Metabolome Using High-Resolution Mass Spectrometry

alexandre TRONEL,morgane Roger-Margueritat,Caroline Plazy,valerie Cunin,Ipsita Mohanty,Pieter C. Dorrestein,Thomas Soranzo,audrey LE GOUELLEC

DOI: https://doi.org/10.1101/2024.09.16.613180

2024-09-19

Abstract:The gut microbiome is a complex ecosystem varying along different gut sections, consisting of metabolites from food, host, and microbes. Microbially-derived metabolites like bile acids and short-chain fatty acids interact with host physiology. Current studies often use fecal samples, which don’t fully represent the upper gut due to stratification. To sample the proximal gut microbiome, endoscopic methods or new non-invasive devices are used. We developed an approach combining untargeted and semi-targeted metabolomics using a Q-Exactive Plus Orbitrap mass spectrometer to profile gut metabolites. We initially selected 49 key metabolites based on specific criteria, validated them through repeatability tests, and created a compound database with TraceFinder software. Our workflow enables molecule annotation in untargeted studies while validating 37 metabolites in semitargeted analyses. This method, applied to clinical trial samples ( ), shows promise in discovering new gut metabolites.

Biochemistry

What problem does this paper attempt to address?

The problem this paper attempts to address is: how to comprehensively analyze metabolites in small intestine and fecal samples by combining untargeted and semi-targeted metabolomics methods, in order to better understand the relationship between the gut microbiome and host health.

Specifically, the paper aims to:
1. **Develop an innovative metabolomics workflow**: Combining untargeted and semi-targeted metabolomics methods for characterizing the small intestine and fecal metabolome. This approach allows for the relative quantification of selected metabolites and can utilize continuously updated databases to reanalyze these metabolites, thereby enhancing the understanding of the gut microbiome-health axis.
2. **Determine the global metabolic profile of small intestine and fecal samples**: Using untargeted metabolomics methods to identify the global metabolic characteristics of the samples and discover new metabolites.
3. **Validate the method in clinical samples**: Applying this method to clinical trial samples (NCT05477069) to demonstrate its capability in identifying and quantifying metabolites, and revealing significant differences in metabolite abundance between small intestine contents and fecal samples, particularly discovering new bile acids through molecular networking.

Through these objectives, the paper hopes to provide a new, more comprehensive approach for studying the gut microbiome and its relationship with host health.